Clinical Spectrum of Adult Henoch-Schönlein Purpura: Diagnostic Challenges and Long-Term Prognostic Considerations

Authors

  • Gede Padmawijaya Universitas Udayana, Indonesia
  • Ketut Suardamana Universitas Udayana, Indonesia

DOI:

https://doi.org/10.58344/ihj.v5i2.860

Keywords:

Henoch-Schönlein Purpura, IgA Vasculitis, Diagnosis, Initial Management

Abstract

Immunoglobulin A vasculitis (IgAV) or Henoch–Schönlein purpura (HSP) is an immune complex-mediated systemic vasculitis that primarily affects small blood vessels in the skin, joints, gastrointestinal tract, and kidneys. Although more common in children, IgAV in adults tends to present with more severe symptoms and a higher risk of long-term kidney disease. IgAV is diagnosed based on clinical and histopathological criteria, with emphasis on non-thrombocytopenic palpable purpura, arthralgia/arthritis, abdominal pain, and/or kidney involvement, along with findings of leucocytoclastic vasculitis with IgA deposition on biopsy. Case Illustration: This case report describes a 20-year-old woman with palpable purpura on the lower legs and hands, arthralgia, a history of prior sore throat, and bronchial asthma with markedly elevated IgE. Laboratory findings showed elevated ESR and CRP; urinalysis was negative; skin biopsy revealed leucocytoclastic vasculitis. The patient was taking hormonal medication, methylprednisolone, and loratadine. This case demonstrates a typical presentation of IgAV in young adults, supported by a history of previous upper respiratory tract infection and atopic predisposition (bronchial asthma with high IgE). Clinical manifestations of palpable purpura on the extremities and arthralgia are highly consistent with IgAV. The leucocytoclastic vasculitis findings on skin biopsy are highly suggestive, although confirmation of IgA deposition remains ideal for definitive diagnosis. Management with corticosteroids and antihistamines aims to alleviate skin and joint inflammation. Long-term prognosis depends on close monitoring for potential development of IgAV nephritis.

References

Ali, Y. (2018). Self-assessment in rheumatology: An essential Q & A study guide. Springer.

Baigrie, D., & Crane, J. S. (2025). Leukocytoclastic vasculitis. In StatPearls. StatPearls Publishing.

Castañeda, S., Quiroga-Colina, P., Floranes, P., Uriarte-Ecenarro, M., Valero-Martínez, C., Vicente-Rabaneda, E. F., et al. (2024). IgA vasculitis (Henoch–Schönlein purpura): An update on treatment. Journal of Clinical Medicine, 13(21), 1–21.

Chen, A. C., Lin, C. L., Shen, T. C., Li, T. C., Sung, F. C., & Wei, C. C. (2016). Association between allergic diseases and risks of HSP and HSP nephritis: A population-based study. Pediatric Research, 79(4), 559–564.

Froberg, P. W., Ruml, A., & Fernandez, J. K. (2025). Henoch-Schönlein purpura without proven immunoglobulin A deposition: A diagnostic distinction. Cureus, 17(4), 1–8.

Heineke, M. H., Ballering, A. V., Jamin, A., Ben Mkaddem, S., Monteiro, R. C., & Van Egmond, M. (2017). New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmunity Reviews, 16(12), 1246–1253.

Ho?evar, A., Rotar, Z., Jur?i?, V., Pižem, J., ?u?nik, S., Vizjak, A., et al. (2016). IgA vasculitis in adults: The performance of the EULAR/PRINTO/PRES classification criteria in adults. Arthritis Research & Therapy, 18(1), 1–5.

Koné-Paut, I., Hofer, M., Van der Hilst, J., Gül, A., Brogan, P., & Manna, R. (2017). Safety, pharmacokinetics and pharmacodynamics of canakinumab in patients with colchicine-resistant FMF: Results from the phase 3 CLUSTER trial.

Kostadinova-Petrova, I., Mitevska, E., & Janeska, B. (2017). Histological characteristics of bruises with different age. Open Access Macedonian Journal of Medical Sciences, 5(7), 813.

Luthfia Wardhani, R., & Ariffatus Saroh, S. (2023). Management of Henoch-Schönlein purpura with gastrointestinal manifestations in children. 4(1), 15–24.

Mahmoud, S., Ghosh, S., Farver, C., Lempel, J., Azok, J., & Renapurkar, R. D. (2016). Pulmonary vasculitis: Spectrum of imaging appearances. Radiologic Clinics of North America, 54(6), 1097–1118.

Maritsi, D. (2017). Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part two. Pediatric Rheumatology.

Mistry, N., Gupta, A., Alavi, A., & Sibbald, R. G. (2015). A review of the diagnosis and management of erythroderma (generalized red skin). Advances in Skin & Wound Care, 28(5), 228–236.

Ozen, S., Marks, S. D., Brogan, P., Groot, N., De Graeff, N., Avcin, T., et al. (2019). European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—The SHARE initiative. Rheumatology, 58(9), 1607–1616.

World Health Organization. (2018). Recognizing neglected tropical diseases through changes on the skin: A training guide for front-line health workers. World Health Organization.

Rasmussen, C., Tisseyre, M., Garon-Czmil, J., Atzenhoffer, M., Guillevin, L., Salem, J. E., et al. (2021). Drug-induced IgA vasculitis in children and adults: Revisiting drug causality using a dual pharmacovigilance-based approach. Autoimmunity Reviews, 20(1).

Reamy, B. V., Servey, J. T., & Williams, P. M. (2020). Henoch-Schönlein purpura (IgA vasculitis): Rapid evidence review. American Family Physician, 102(4), 229–233.

Roache-Robinson, P., Killeen, R. B., & Hotwagner, D. T. (2025). IgA vasculitis (Henoch-Schönlein purpura). In StatPearls. StatPearls Publishing.

Ruperto, N., Ozen, S., Pistorio, A., Dolezalova, P., Brogan, P., Cabral, D. A., et al. (2010). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Annals of the Rheumatic Diseases, 69(5), 790–797.

Song, Y., Huang, X., Yu, G., Qiao, J., Cheng, J., Wu, J., et al. (2021). Pathogenesis of IgA vasculitis: An up-to-date review. Frontiers in Immunology, 12, 1–10.

Urakov, A. (2020). What are bruises? Causes, symptoms, diagnosis, treatment, remedies. IP International Journal of Comprehensive and Advanced Pharmacology, 5(1), 1–5.

Downloads

Published

2026-06-18